Success Metrics

Active Trials
0(0%)

Phase Distribution

Ph phase_3
1
50%
Ph phase_1
1
50%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 3Large-scale testing
1(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Active(1)
Other(1)

Detailed Status

unknown1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Phase 11 (50.0%)
Phase 31 (50.0%)

Trials by Status

unknown150%
not_yet_recruiting150%

Recent Activity

0 active trials
Showing 2 of 2
not_yet_recruitingphase_3

Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma

NCT07187960
unknownphase_1

Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors

NCT05489276

Clinical Trials (2)

Showing 2 of 2 trials
NCT07187960Phase 3

Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma

Not Yet Recruiting
NCT05489276Phase 1

Clinical Trial of TQB2825 in Subjects With CD20 Positive Hematological Tumors

Unknown

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2